Achaogen Share Price

AKAOQ

US0044491043

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

12/20/12	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/20/29	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	6L 6L 5L 5L 9L 6.11Cr 9L 62.8L 24.23L 3.12Cr 23.99L 23.46L 10Cr	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	1.95Cr 1.7Cr 1.6Cr 1.46Cr 2.74Cr 186.06Cr 2.74Cr 19Cr 7.38Cr 95Cr 7.31Cr 7.15Cr 306.46Cr	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

12/20/12	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/20/29	Achaogen, Inc. Went Out of Business	CI
29/20/29	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
22/20/22	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
21/20/21	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
30/20/30	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
09/20/09	Motion for Asset Sale Approved for Achaogen, Inc.	CI
29/19/29	Motion for Asset Sale Filed by Achaogen, Inc.	CI
24/19/24	Final DIP Financing Approved for Achaogen, Inc.	CI
29/19/29	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
13/19/13	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
30/19/30	Achaogen, Inc. Announces Management Changes	CI
23/19/23	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	1.12Cr 97.62L 91.69L 83.75L 1.57Cr 106.81Cr 1.57Cr 11Cr 4.24Cr 55Cr 4.2Cr 4.1Cr 175.92Cr	87.28L 76.25L 71.61L 65.41L 1.23Cr 83Cr 1.23Cr 8.58Cr 3.31Cr 43Cr 3.28Cr 3.21Cr 137.4Cr
Net income	-13Cr -11Cr -10Cr -9.41Cr -18Cr -1.2TCr -18Cr -123.5Cr -48Cr -613.25Cr -47Cr -46Cr -1.98TCr	-19Cr -16Cr -15Cr -14Cr -26Cr -1.78TCr -26Cr -183.37Cr -71Cr -910.53Cr -70Cr -69Cr -2.94TCr
Net Debt	-14Cr -12Cr -12Cr -11Cr -20Cr -1.37TCr -20Cr -140.43Cr -54Cr -697.3Cr -54Cr -52Cr -2.25TCr	1.88Cr 1.64Cr 1.54Cr 1.41Cr 2.65Cr 179.96Cr 2.65Cr 19Cr 7.14Cr 92Cr 7.07Cr 6.92Cr 296.4Cr

Achaogen Share Price

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news: Achaogen

Financials

Company Profile